疫苗生产设施
During 2018, only Influenza vaccines were manufactured at this facility: two distinct products for the market, Agrippal® and Fluad®, (seasonal influenza strain presentations). The Fluvirin ® product is no longer manufactured.
Influenza: Manufacture of influenza vaccine based on WHO recommendations
The BioReliance® Services business of Merck KGaA is primarily a Contract Testing Organisation, providing biosafety testing services for a wide range of global, biopharmaceutical companies.
The Glasgow facility also has a biomanufacturing facility. No products are manufactured for direct sale - only contract manufacturing for others. Typical products produced are (i) Cell Banks, (ii) Virus Seed Stocks and (iii) Viral Vectors.
Valneva manufactures Japanese Encephalitis Viral vaccine (IXIARO®/JESPECT®) at its cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The vaccine is designed to protect travellers and military against Japanese encephalitis (JE), the leading cause of viral neurological disease & disability in Asia.